NICE’s final draft guidance (published Friday 3 May 2024), recommends voxelotor (also called Oxbryta and made by Pfizer) with or without another treatment for SCD called hydroxycarbamide.
The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...
The evaluation committee considered evidence submitted by Merck Sharp & Dohme, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
The heart needs a constant supply of blood. In coronary heart disease, this blood supply gets interrupted or blocked by a build-up of fatty substances in the coronary arteries. Drug eluting stents are ...
If data collection is expected to end later than planned, the company should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance if ...
Pembrolizumab (Keytruda, MSD) is indicated for 'the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous ...
If data collection is expected to end later than planned, the company should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance if ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
This topic was considered by NICE's medical technologies advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technologies to ...
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence ...
There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results